General justification in terms of effectiveness and toxicities for the use of nanocarriers
Abstract This review highlights the potential benefits and drawbacks of using nanocarriers as drug delivery systems. Nanocarriers have been widely utilized to enhance drug efficiency, overcome drug resistance, and reduce adverse effects. However, the interaction between nanocarriers and biological systems can lead to toxic responses. Therefore, it is crucial to carefully select optimized nanocarriers to minimize toxicity and maximize efficiency. Every type of nanocarrier has its own advantages and disadvantages. Hybrid nanocarriers have been engineered to address the limitations of existing nanocarriers and are considered more suitable for developing new formulations. The article discusses various aspects of nanocarriers, including their applicability, potential toxicity, and strategies for utilizing appropriate nanocarriers in nanoformulations. To mitigate the toxicity of nanocarriers, several approaches can be employed, such as PEGylation, coating, charge coating, and injections of free PEG; moreover, by modifying the preparation method or utilizing hybrid nanocarriers, the efficiency of drug delivery systems can be improved. Overall, the article emphasizes the importance of selecting appropriate nanocarriers and employing strategies to reduce toxicity while enhancing drug delivery efficiency..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
---|---|
Enthalten in: |
Journal of nanoparticle research - 25(2023), 9 vom: Sept. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Handali, Somayeh [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Drug delivery |
---|
Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
---|
doi: |
10.1007/s11051-023-05826-y |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR052987698 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR052987698 | ||
003 | DE-627 | ||
005 | 20231006062603.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230906s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11051-023-05826-y |2 doi | |
035 | |a (DE-627)SPR052987698 | ||
035 | |a (SPR)s11051-023-05826-y-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Handali, Somayeh |e verfasserin |4 aut | |
245 | 1 | 0 | |a General justification in terms of effectiveness and toxicities for the use of nanocarriers |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
520 | |a Abstract This review highlights the potential benefits and drawbacks of using nanocarriers as drug delivery systems. Nanocarriers have been widely utilized to enhance drug efficiency, overcome drug resistance, and reduce adverse effects. However, the interaction between nanocarriers and biological systems can lead to toxic responses. Therefore, it is crucial to carefully select optimized nanocarriers to minimize toxicity and maximize efficiency. Every type of nanocarrier has its own advantages and disadvantages. Hybrid nanocarriers have been engineered to address the limitations of existing nanocarriers and are considered more suitable for developing new formulations. The article discusses various aspects of nanocarriers, including their applicability, potential toxicity, and strategies for utilizing appropriate nanocarriers in nanoformulations. To mitigate the toxicity of nanocarriers, several approaches can be employed, such as PEGylation, coating, charge coating, and injections of free PEG; moreover, by modifying the preparation method or utilizing hybrid nanocarriers, the efficiency of drug delivery systems can be improved. Overall, the article emphasizes the importance of selecting appropriate nanocarriers and employing strategies to reduce toxicity while enhancing drug delivery efficiency. | ||
650 | 4 | |a Nanocarrier |7 (dpeaa)DE-He213 | |
650 | 4 | |a Toxicity |7 (dpeaa)DE-He213 | |
650 | 4 | |a Drug delivery |7 (dpeaa)DE-He213 | |
650 | 4 | |a Immune system |7 (dpeaa)DE-He213 | |
650 | 4 | |a Hybrid carrier |7 (dpeaa)DE-He213 | |
650 | 4 | |a selection strategy |7 (dpeaa)DE-He213 | |
700 | 1 | |a Rezaei, Mohsen |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of nanoparticle research |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1999 |g 25(2023), 9 vom: Sept. |w (DE-627)SPR016066200 |w (DE-600)2017013-0 |x 1572-896X |7 nnns |
773 | 1 | 8 | |g volume:25 |g year:2023 |g number:9 |g month:09 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11051-023-05826-y |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 25 |j 2023 |e 9 |c 09 |